­
­
­
­

Inventi Impact: Pathology

Articles

  • Inventi:hpt/33169/20
    Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
    Research 2021 : January - March
    Tarek M Owaidah, Hazzaa A Alzahrani, Nouf S Al-Numair, Abdulmjeed O Alnosair, Amelita M Aguilos, Mahasen Saleh

    Background. The one-stage assay is the most common method to measure factor VIII activity (FVIII : C) in hemophilia A patients.\nThe chromogenic assay is another two-stage test involving purified coagulation factors followed by factor Xa-specific chromogenic\nsubstrate. Aim. This study aimed to assess the discrepancy and correlation between the chromogenic and one-stage assays in\nmeasuring FVIII :C levels in hemophilia patients receiving Extended Half-Life ........................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Owaidah, Tarek M., et al. \"Assessing the Performance of Extended Half-Life Coagulation Factor\nVIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.\" Advances in Hematology 2020\n(2020).\nhttps://doi.org/10.1155/2020/8768074\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text